<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Brown AL</submitter><funding>St. Baldrick&amp;apos;s Foundation</funding><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><funding>Leukemia Research Foundation</funding><funding>Cancer Prevention and Research Institute of Texas</funding><pagination>464-473</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7914130</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>61(3)</volume><pubmed_abstract>&lt;h4>Context&lt;/h4>Cancer-related fatigue (CRF) is one of the most distressing and persistent symptoms reported during pediatric acute lymphoblastic leukemia (ALL) therapy; however, information on the pathways underlying CRF severity is limited.&lt;h4>Objectives&lt;/h4>We conducted global metabolomics profiling of cerebrospinal fluid (CSF) samples to provide insight into the underlying mechanisms of CRF.&lt;h4>Methods&lt;/h4>Fatigue in pediatric ALL patients (2012-2017) was assessed during postinduction therapy approximately six months after diagnosis. Postinduction CSF was collected from 171 participants, comprising discovery (n = 86) and replication (n = 85) cohorts. We also conducted secondary validation using diagnostic CSF from 48 replication cohort participants. CSF metabolomic profiling was performed using gas chromatography-mass spectrometry (MS) and liquid chromatography-MS/MS. Kendall's rank correlation was used to evaluate associations between metabolite abundance and CRF. False discovery rate was used to account for multiple comparisons.&lt;h4>Results&lt;/h4>Participants were 56% males and 59% Hispanic with a mean age at diagnosis of 8.5 years. A total of 274 CSF-derived metabolites were common to the discovery and replication cohorts. Eight metabolites were significantly associated with fatigue in the discovery cohort (P &lt; 0.05), of which three were significant in the replication cohort, including false discovery rate-corrected associations with gamma-glutamylglutamine (P&lt;sub>combined&lt;/sub> = 6.2E-6) and asparagine (P&lt;sub>combined&lt;/sub> = 3.5E-4). Notably, the abundance of gamma-glutamylglutamine in diagnostic CSF samples was also significantly associated with fatigue (P = 0.0062).&lt;h4>Conclusion&lt;/h4>The metabolites identified in our assessment have been implicated in neurotransmitter transportation and glutathione recycling, suggesting that glutamatergic pathways or oxidative stress may contribute to ALL-associated CRF. This information could inform targeted therapies for reducing CRF in at-risk individuals.</pubmed_abstract><journal>Journal of pain and symptom management</journal><pubmed_title>Cerebrospinal Fluid Metabolomic Profiles Associated With Fatigue During Treatment for Pediatric Acute Lymphoblastic Leukemia.</pubmed_title><pmcid>PMC7914130</pmcid><funding_grant_id>K07 CA218362</funding_grant_id><pubmed_authors>Raghubar KP</pubmed_authors><pubmed_authors>Kahalley LS</pubmed_authors><pubmed_authors>Bernhardt MB</pubmed_authors><pubmed_authors>Scheurer ME</pubmed_authors><pubmed_authors>Hockenberry MJ</pubmed_authors><pubmed_authors>Woodhouse JP</pubmed_authors><pubmed_authors>Brown AL</pubmed_authors><pubmed_authors>Sok P</pubmed_authors><pubmed_authors>Taylor O</pubmed_authors><pubmed_authors>Lupo PJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cerebrospinal Fluid Metabolomic Profiles Associated With Fatigue During Treatment for Pediatric Acute Lymphoblastic Leukemia.</name><description>&lt;h4>Context&lt;/h4>Cancer-related fatigue (CRF) is one of the most distressing and persistent symptoms reported during pediatric acute lymphoblastic leukemia (ALL) therapy; however, information on the pathways underlying CRF severity is limited.&lt;h4>Objectives&lt;/h4>We conducted global metabolomics profiling of cerebrospinal fluid (CSF) samples to provide insight into the underlying mechanisms of CRF.&lt;h4>Methods&lt;/h4>Fatigue in pediatric ALL patients (2012-2017) was assessed during postinduction therapy approximately six months after diagnosis. Postinduction CSF was collected from 171 participants, comprising discovery (n = 86) and replication (n = 85) cohorts. We also conducted secondary validation using diagnostic CSF from 48 replication cohort participants. CSF metabolomic profiling was performed using gas chromatography-mass spectrometry (MS) and liquid chromatography-MS/MS. Kendall's rank correlation was used to evaluate associations between metabolite abundance and CRF. False discovery rate was used to account for multiple comparisons.&lt;h4>Results&lt;/h4>Participants were 56% males and 59% Hispanic with a mean age at diagnosis of 8.5 years. A total of 274 CSF-derived metabolites were common to the discovery and replication cohorts. Eight metabolites were significantly associated with fatigue in the discovery cohort (P &lt; 0.05), of which three were significant in the replication cohort, including false discovery rate-corrected associations with gamma-glutamylglutamine (P&lt;sub>combined&lt;/sub> = 6.2E-6) and asparagine (P&lt;sub>combined&lt;/sub> = 3.5E-4). Notably, the abundance of gamma-glutamylglutamine in diagnostic CSF samples was also significantly associated with fatigue (P = 0.0062).&lt;h4>Conclusion&lt;/h4>The metabolites identified in our assessment have been implicated in neurotransmitter transportation and glutathione recycling, suggesting that glutamatergic pathways or oxidative stress may contribute to ALL-associated CRF. This information could inform targeted therapies for reducing CRF in at-risk individuals.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Mar</publication><modification>2025-04-05T14:05:42.822Z</modification><creation>2025-04-05T14:05:42.822Z</creation></dates><accession>S-EPMC7914130</accession><cross_references><pubmed>32889041</pubmed><doi>10.1016/j.jpainsymman.2020.08.030</doi></cross_references></HashMap>